Closed

Navy Multi-Topic 2021 - Advanced Biomedical Product Development in Support of Naval Operations

Medical Technology Enterprise Consortium (MTEC)

REQUEST ISSUE DATE

February 22, 2021

DUE DATE

March 22, 2021

DOCUMENTS

1 Documents

Awardees

Member

Immuron Ltd

Immuron Ltd is a publicly listed Australian biopharmaceutical company focused on developing and commercializing a novel class of specifically targeted polyclonal antibodies. The company aims to address significant unmet medical needs, particularly in treating gastrointestinal disorders caused by pathogenic bacteria. Immuron has established partnerships with leading research institutions and companies to enhance its product development and manufacturing capabilities. The company is currently advancing its drug candidates through clinical development, targeting conditions such as Campylobacteriosis, recurrent Clostridiodes difficile infections, and travelers’ diarrhea. Immuron is also engaged in various scientific studies and collaborations to further its research and product efficacy. The company has a proprietary technology platform and is committed to transforming treatment paradigms for gastrointestinal health.

Funding (ceiling)

$3,433,758

Member

Boston University

Boston University is a major research institution committed to leading breakthroughs across various disciplines. The Office of Research supports and advances research excellence, fostering collaboration among researchers, industry partners, and government leaders to address significant societal challenges.

Funding (ceiling)

$999,986.82

Member

Athena GTX

Athena GTX is dedicated to advancing wireless, mobile, patient-worn monitoring solutions for both military and civilian markets. The company focuses on connecting patients and providers through state-of-the-art medical and communication technology, developed and produced in Iowa. Athena GTX aims to enhance patient outcomes by integrating innovative wireless technology with reliable devices, supporting first responders and medical professionals in various challenging environments.

Funding (ceiling)

$2,396,377.12

Member

Imbed Biosciences

Imbed Biosciences is a privately held medical device company that specializes in the development of advanced devices for the treatment of burns, ulcers, and soft-tissue repair. The company is committed to providing innovative solutions that improve patient care and outcomes through its patented Microlyte® Matrix technology.

Funding (ceiling)

$440,620.24

Member

RevMedx

RevMedx is dedicated to saving lives by creating groundbreaking hemorrhage control solutions. Their devices, designed specifically for combat medics and civilian first responders, are transforming the treatment of life-threatening bleeding.

Funding (ceiling)

$6,045,374.5

Member

Terumo Blood and Cell Technologies

Terumo Blood and Cell Technologies is a global leader in medical technology, specializing in blood and cell-based therapies. With over 7,900 team members, the company is dedicated to advancing healthcare by providing innovative solutions for blood collection, processing, and storage. Their mission is to empower healthcare providers with the tools and insights needed to deliver high-quality care to patients worldwide. Terumo BCT is committed to unlocking the potential of blood and cells, offering a range of products and services that support lifesaving transfusions and next-generation therapies for diseases like cancer. The company is part of the Terumo Group, which has been contributing to society through healthcare for over a century.

Funding (ceiling)

$11,992,148.46

Member

GE HealthCare Technology & Innovation Center

The GE HealthCare Technology & Innovation Center (HTIC) traces its roots to America's first industrial research facility, established by General Electric in 1900. Today, HTIC scientists tackle healthcare challenges through federal funding, academic collaboration, and private sector development. HTIC enhances GE HealthCare competitiveness through development of innovative technologies that enable creation of differentiated and disruptive products. HTIC engages in exploratory research in collaboration with clinicians and academia, guided by societal needs and governmental priorities to discover new markets. With operations in Niskayuna, NY, USA and Bangalore, India, HTIC translates federal research investments into clinical applications.

Funding (ceiling)

$5,636,376

Member

MassBiologics

MassBiologics, part of UMass Chan Medical School, is the only nonprofit, FDA-licensed manufacturer of vaccines and biologics in the United States. With over 100 years of experience, it is dedicated to improving public health through the research, development, and production of biologic products, including vaccines and monoclonal antibodies.

Funding (ceiling)

$4,718,756

View All 9 Awardees

Purpose

This solicitation, issued by MTEC, represents a Request for Project Proposals (RPP) for MTEC support of the Naval Medical Research Center (NMRC) Naval Advanced Medical Development (NAMD) program. Proposals selected for award as a result of this RPP will be awarded under the authority of 10 U.S.C. § 2371b. The award(s) will be managed by the NAMD program office within Naval Medical Research Center.

The purpose of the multiple topic area (“multi-topic”) Request for Project Proposals (RPP) is focused on the advancement of engineering and medical prototypes and knowledge products related to a broad range of medical technological needs identified in the focus areas listed below. Relevance to the enhanced readiness and resilience of Navy and Marine Corps health and performance is a key feature of this RPP.

Focus Area #1: Combat Casualty Wound and Infection Care

Focus Area #2: Enterotoxigenic Escherichia Coli (ETEC) Disease Research

Focus Area #3: Human Performance / Physiological Episodes